Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
03 Novembro 2022 - 5:00AM
Company announcement – No. 49 / 2022
Zealand Pharma Hosts Conference Call on
November 10
at 4pm CET (10am ET) to Present
Third Quarter Results for
2022
Copenhagen, Denmark and Boston, MA, U.S. November 3,
2022 – a Zealand Pharma A/S (CVR-no. 20045078) a
biotechnology company focused on the discovery and development of
innovative peptide-based medicines, announced that it will host a
conference call on November 10, 2022 at 4 pm CET (10 am ET)
following the announcement of results for the third quarter of
2022.
Presenting during the call will be President and Chief Executive
Officer Adam Steensberg, Chief Financial Officer Henriette
Wennicke, and Chief Medical Officer David Kendall. The presentation
will be followed by a Q&A session. The conference call will be
conducted in English.
Telephone dial-in information and a unique personal access PIN
will be provided upon registration via the following link,
https://register.vevent.com/register/BI2233344c2eff4f40be51448707df4e03.
A live audio webcast of the call, including an accompanying
slide presentation, will be available via the following
link, https://edge.media-server.com/mmc/p/untoz3rk, and will
be accessible on the Investor section of Zealand’s website
(www.zealandpharma.com/events-cal). A recording of the event will
be available on the Investor section of Zealand’s website after the
call.
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In addition, license
collaborations with Boehringer Ingelheim and AstraZeneca create
opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.
Zealand was founded in 1998 and headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please
visit http://www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events. Such forward-looking
statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially
from expectations set forth herein and may cause any or all of such
forward-looking statements to be incorrect. If any or all of such
forward-looking statements prove to be incorrect, our actual
results could differ materially and adversely from those
anticipated or implied by such statements. All such forward-looking
statements speak only as of the date of this release and are based
on information available to Zealand Pharma as of the date of this
release.
Contacts:Anna
Krassowska, PhDVice President, Investor Relations & Corporate
CommunicationsZealand PharmaEmail: ank@zealandpharma.com
David Rosen (U.S. Media)Argot PartnersEmail:
media@zealandpharma.com
Zealand Pharma AS (NASDAQ:ZEAL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zealand Pharma AS (NASDAQ:ZEAL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024